Clinical trial results:
An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated LDL-C (ORION-3)

Summary

EudraCT number	2016-003815-37
Trial protocol	GB DE NL
Global end of trial date	17 December 2021

Results information

Result version number	v2 (current)
This version publication date	12 April 2023
First version publication date	15 December 2022
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	MDCO-PCS-16-01

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03060577
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharmaceuticals
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 December 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 December 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 April 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 56
Country: Number of subjects enrolled	Germany: 49
Country: Number of subjects enrolled	United Kingdom: 69
Country: Number of subjects enrolled	Netherlands: 136
Country: Number of subjects enrolled	United States: 72
Worldwide total number of subjects	382
EEA total number of subjects	185

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	198
From 65 to 84 years	182
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

Participants were recruited from 51 sites in 5 countries.

Pre-assignment

Screening details:

After completion of study MDCO-PCS-15-01, participants were screened to fulfill all inclusion and exclusion criteria.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Inclisiran-only

Arm description:

Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter up to Year 4.

Arm type	Experimental
Investigational medicinal product name	Inclisiran
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.

Investigational medicinal product name	Evolocumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336.

Arm title	Switching

Arm description:

Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter up to Year 4.

Arm type	Experimental
Investigational medicinal product name	Inclisiran
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.

Number of subjects in period 1	Inclisiran-only	Switching
Started	290	92
Safety Analysis Set	284	90
Completed	233	80
Not completed	57	12
Consent withdrawn by subject	25	5
Physician decision	4	3
Adverse Event	9	1
Death	7	1
Other	8	2
Inclusion/Exclusion	1	-
Lost to follow-up	3	-

Baseline characteristics

Reporting groups	
Reporting group title	Inclisiran-only
Reporting group description:	
Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter up to Year 4.	
Reporting group title	Switching
Reporting group description:	
Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter up to Year 4.	

Reporting group values	Inclisiran-only	Switching	Total
Number of subjects	290	92	382
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	145	53	198
From 65-84 years	144	38	182
85 years and over	1	1	2
Age Continuous Units: Year			
arithmetic mean	63.3	61.9	
standard deviation	± 11.14	± 10.56	-
Sex: Female, Male Units: Participants			
Female	102	37	139
Male	188	55	243
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	15	7	22
Not Hispanic or Latino	275	85	360
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Inclisiran-only
Reporting group description:	
Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter up to Year 4.	
Reporting group title	Switching
Reporting group description:	
Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter up to Year 4.	

Primary: Percentage Change in LDL-C from baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)

End point title	Percentage Change in LDL-C from baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)[1][2]
End point description:	
Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	
End point type	Primary
End point timeframe:	
Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This endpoint is applicable to the inclisiran arm only.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)	-47.48 (-50.69 to -44.27)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Change in LDL-C from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Percentage Change in LDL-C from baseline of the ORION-1 study (Inclisiran Arm)[3]

End point description:

Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-49.43 (-52.27 to -46.58)			
Day 360 (n=269)	-37.14 (-40.95 to -33.32)			
Day 720 (n=253)	-38.43 (-41.75 to -35.11)			
Day 1080 (n=225)	-51.07 (-54.75 to -47.39)			
Day 1440 (n=232)	-46.74 (-50.71 to -42.78)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change in LDL-C from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Absolute Change in LDL-C from baseline of the ORION-1 study (Inclisiran Arm)[4]

End point description:

Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: mg/dL				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-62.51 (-66.76 to -58.25)			
Day 360 (n=269)	-47.96 (-52.56 to -43.35)			
Day 720 (n=253)	-49.44 (-54.25 to -44.64)			
Day 1080 (n=225)	-63.34 (-68.76 to -57.92)			
Day 1440 (n=232)	-60.04 (-65.81 to -54.27)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Change in PCSK9 levels from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Percentage Change in PCSK9 levels from baseline of the ORION-1 study (Inclisiran Arm)[5]

End point description:

Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-71.80 (-73.17 to -70.44)			
Day 360 (n=271)	-63.79 (-65.79 to -61.80)			
Day 720 (n=253)	-62.17 (-64.46 to -59.88)			
Day 1440 (n=228)	-69.54 (-71.19 to -67.89)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change in PCSK9 levels from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Absolute Change in PCSK9 levels from baseline of the ORION-1 study (Inclisiran Arm)[6]

End point description:

Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: ug/L				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-314.07 (-328.69 to -299.45)			
Day 360 (n=271)	-280.88 (-295.71 to -266.06)			
Day 720 (n=253)	-275.78 (-291.91 to -259.64)			
Day 1440 (n=228)	-314.34 (-331.22 to -297.46)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Change in Triglycerides from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Percentage Change in Triglycerides from baseline of the

	ORION-1 study (Inclisiran Arm)[7]

End point description:

Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-1.71 (-6.42 to 3.00)			
Day 210 (n=277)	-3.35 (-9.12 to 2.41)			
Day 1440 (n=232)	0.73 (-8.23 to 9.69)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change in Triglycerides from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Absolute Change in Triglycerides from baseline of the ORION-1 study (Inclisiran Arm)[8]

End point description:

Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: mg/dL				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-14.61 (-22.15 to -7.08)			
Day 210 (n=277)	-11.96 (-23.78 to -0.14)			
Day 1440 (n=232)	-14.83 (-25.75 to -3.90)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Change in Apolipoprotein B from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Percentage Change in Apolipoprotein B from baseline of the ORION-1 study (Inclisiran Arm)[9]

End point description:

Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-40.43 (-42.57 to -38.29)			
Day 210 (n=277)	-36.65 (-39.06 to -34.23)			
Day 1440 (n=226)	-33.66 (-37.18 to -30.15)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change in Apolipoprotein B from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Absolute Change in Apolipoprotein B from baseline of the ORION-1 study (Inclisiran Arm)[10]

End point description:

Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: mg/dL				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-42.63 (-45.22 to -40.04)			
Day 210 (n=277)	-38.36 (-41.19 to -35.54)			
Day 1440 (n=226)	-36.26 (-40.01 to -32.52)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Change in Lipoprotein-a from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Percentage Change in Lipoprotein-a from baseline of the ORION-1 study (Inclisiran Arm)[11]

End point description:

Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: Percentage Change				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-15.88 (-19.48 to -12.28)			
Day 210 (n=277)	9.29 (4.42 to 14.16)			
Day 1440 (n=225)	-5.24 (-9.86 to -0.61)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change in Lipoprotein-a from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Absolute Change in Lipoprotein-a from baseline of the ORION-1 study (Inclisiran Arm)[12]

End point description:

Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	277			
Units: nmol/L				
arithmetic mean (confidence interval 95%)				
Day 30 (n=277)	-8.52 (-12.25 to -4.79)			
Day 210 (n=277)	-4.94 (-8.67 to -1.20)			
Day 1440 (n=225)	-4.78 (-9.63 to 0.06)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with ≥50% LDL-C Reduction from baseline of the ORION-1 study (Inclisiran Arm)

End point title	Number of Participants with ≥50% LDL-C Reduction from baseline of the ORION-1 study (Inclisiran Arm)[13]

End point description:

Number of Participants with ≥50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.

End point type	Secondary

End point timeframe:

Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	284			
Units: Participants				
Day 30 (n=284)	161			
Day 360 (n=271)	99			
Day 720 (n=255)	97			
Day 1440 (n=234)	122			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)

End point title	Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)[14]

End point description:

Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL at any time point.

End point type	Secondary

End point timeframe:

From the start of treatment in ORION-3 to 90 days after end of treatment, assessed up to maximum duration of 4 years

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint is applicable to the inclisiran arm only.

End point values	Inclisiran-only			
Subject group type	Reporting group			
Number of subjects analysed	284			
Units: Participants				
LDL-C level <25 mg/dL	82			
LDL-C level <50 mg/dL	175			
LDL-C level <70 mg/dL	225			
LDL-C level <100 mg/dL	265			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from first dose of study treatment in ORION-3 up to end of study visit, assessed up to maximum duration of 4 years.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.1

Reporting groups

Reporting group title	Inclisiran only arm

Reporting group description:

Participants received subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter up to Year 4.

Reporting group title	Switching arm after Day 360 visit

Reporting group description:

Participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter up to Year 4.

Reporting group title	Switching arm up to Day 360 visit

Reporting group description:

Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336.

Serious adverse events	Inclisiran only arm	Switching arm after Day 360 visit	Switching arm up to Day 360 visit
Total subjects affected by serious adverse events			
subjects affected / exposed	104 / 284 (36.62%)	30 / 87 (34.48%)	16 / 90 (17.78%)
number of deaths (all causes)	7	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hodgkin's disease stage IV			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glottis carcinoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Follicular lymphoma			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma recurrent			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			

subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian fibroma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular seminoma (pure) stage I			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testis cancer			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Intermittent claudication			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm rupture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giant cell arteritis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	0 / 284 (0.00%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular stent restenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Epistaxis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol withdrawal syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-traumatic stress disorder			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulse abnormal			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaesthetic complication cardiac			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Humerus fracture			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound complication			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pain			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	7 / 284 (2.46%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	4 / 284 (1.41%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery occlusion			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Coronary artery stenosis			

subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve disease			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular extrasystoles			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			

subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Nervous system disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ileus			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiploic appendagitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Swollen tongue			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic fibrosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Diabetic foot			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral perforation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoporosis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	6 / 284 (2.11%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Arthralgia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Escherichia sepsis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cellulitis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected bite			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Inclisiran only arm	Switching arm after Day 360 visit	Switching arm up to Day 360 visit
Total subjects affected by non-serious adverse events			
subjects affected / exposed	271 / 284 (95.42%)	77 / 87 (88.51%)	78 / 90 (86.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	11 / 284 (3.87%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	13	3	0
Blepharal papilloma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Bowen's disease			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Malignant melanoma			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0

Fibroma			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Haemangioma of liver			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypergammaglobulinaemia benign monoclonal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Intraductal papillary mucinous neoplasm			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lipoma			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	2	1	2
Colon adenoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 284 (0.00%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Oral papilloma			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Ovarian fibroma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Papilloma			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Phaeochromocytoma			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Plasma cell myeloma			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Prostatic adenoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Seborrhoeic keratosis			
subjects affected / exposed	0 / 284 (0.00%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Meningioma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Aortic aneurysm			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	2	2	0
Aortic arteriosclerosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Aortic dilatation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Aortic stenosis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Deep vein thrombosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Extremity necrosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Flushing			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Hot flush			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypertension			
subjects affected / exposed	42 / 284 (14.79%)	17 / 87 (19.54%)	2 / 90 (2.22%)
occurrences (all)	47	18	2
Orthostatic hypotension			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypertensive urgency			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypotension			
subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	6	1	0
Intermittent claudication			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Lymphoedema			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hypertensive crisis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	2	0
Peripheral arterial occlusive disease			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	4	1	0
Peripheral coldness			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Varicose vein			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Peripheral venous disease			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Post thrombotic syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Thrombosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Varicophlebitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Peripheral vascular disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Asthenia			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Chest discomfort			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	5	1	0
Chest pain			
subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	6	1	1
Chills			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Complication of device insertion			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Gait disturbance			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cyst			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Discomfort			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Drug intolerance			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	2
Face oedema			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	23 / 284 (8.10%)	10 / 87 (11.49%)	3 / 90 (3.33%)
occurrences (all)	26	11	3
Feeling abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Crepitations			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hernia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Injection site vesicles			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Injection site bruising			
subjects affected / exposed	4 / 284 (1.41%)	3 / 87 (3.45%)	4 / 90 (4.44%)
occurrences (all)	5	3	6
Injection site discolouration			

subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Injection site erythema			
subjects affected / exposed	12 / 284 (4.23%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	21	4	0
Injection site haematoma			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Injection site haemorrhage			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Injection site oedema			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Injection site pain			
subjects affected / exposed	12 / 284 (4.23%)	4 / 87 (4.60%)	0 / 90 (0.00%)
occurrences (all)	23	4	0
Injection site paraesthesia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Injection site pruritus			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Injection site rash			
subjects affected / exposed	8 / 284 (2.82%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	14	1	0
Injection site reaction			
subjects affected / exposed	16 / 284 (5.63%)	4 / 87 (4.60%)	2 / 90 (2.22%)
occurrences (all)	33	6	2
Injection site urticaria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Influenza like illness			
subjects affected / exposed	15 / 284 (5.28%)	3 / 87 (3.45%)	2 / 90 (2.22%)
occurrences (all)	19	3	2
Injection site warmth			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	2
Medical device complication			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nodule			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	13 / 284 (4.58%)	4 / 87 (4.60%)	1 / 90 (1.11%)
occurrences (all)	17	4	1
Oedema peripheral			
subjects affected / exposed	11 / 284 (3.87%)	6 / 87 (6.90%)	2 / 90 (2.22%)
occurrences (all)	11	6	2
Pain			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Peripheral swelling			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	4	1	1
Polyp			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	4	0	1
Vessel puncture site bruise			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site induration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Malaise			

subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Immune system disorders			
Allergy to animal			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Allergy to arthropod bite			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Allergy to arthropod sting			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Food allergy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	2
Hypersensitivity			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Mite allergy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Seasonal allergy			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	2 / 90 (2.22%)
occurrences (all)	4	2	2
Drug hypersensitivity			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Rubber sensitivity			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Breast tenderness			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Atrophic vulvovaginitis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Balanoposthitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Benign prostatic hyperplasia			
subjects affected / exposed	8 / 284 (2.82%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	8	4	0
Breast disorder female			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Breast pain			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Cervix disorder			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Erectile dysfunction			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Genital rash			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gynaecomastia			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Haematospermia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Heavy menstrual bleeding			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Menopausal symptoms			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Penile erythema			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Prostatitis			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Pruritus genital			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Scrotal pain			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Spermatocele			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Testicular swelling			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Uterine polyp			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Vaginal dysplasia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal pain			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal pruritus			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Abnormal uterine bleeding			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal			

disorders			
Dyspnoea			
subjects affected / exposed	22 / 284 (7.75%)	5 / 87 (5.75%)	2 / 90 (2.22%)
occurrences (all)	22	6	2
Bronchospasm			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	7 / 284 (2.46%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	11	3	2
Cough			
subjects affected / exposed	22 / 284 (7.75%)	5 / 87 (5.75%)	1 / 90 (1.11%)
occurrences (all)	25	5	1
Dry throat			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Asthma			
subjects affected / exposed	10 / 284 (3.52%)	4 / 87 (4.60%)	1 / 90 (1.11%)
occurrences (all)	13	4	1
Dyspnoea exertional			
subjects affected / exposed	10 / 284 (3.52%)	5 / 87 (5.75%)	0 / 90 (0.00%)
occurrences (all)	10	5	0
Emphysema			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	10 / 284 (3.52%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	11	0	1
Hiccups			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypoxia			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Lung infiltration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pneumothorax			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Nasal obstruction			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Nasal polyps			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nasal septum deviation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal pain			
subjects affected / exposed	8 / 284 (2.82%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	8	1	1
Pleural effusion			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Nasal congestion			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Pulmonary calcification			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pulmonary embolism			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Pulmonary hypertension			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Pulmonary mass			

subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Reflux laryngitis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Sinus disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Respiratory distress			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	4
Respiratory tract congestion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences (all)	1	0	2
Sinonasal obstruction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Sinus congestion			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Respiratory disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Sinus polyp			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Sleep apnoea syndrome			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Sneezing			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	3	0	1
Throat irritation			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract irritation			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Psychiatric disorders			
Acute stress disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Adjustment disorder with depressed mood			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Agitation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Alcoholism			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	4	1	2
Anxiety disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Disorientation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Confusional state			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Delirium			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Depressed mood			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Depression			
subjects affected / exposed	12 / 284 (4.23%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	12	0	0
Burnout syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Emotional disorder			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Emotional distress			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Fear			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Indifference			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	10 / 284 (3.52%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	10	1	1
Panic attack			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Seasonal affective disorder			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Stress			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nightmare			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Product issues			
Device dislocation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Prosthetic cardiac valve failure			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatic cyst			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Cholecystitis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Cholelithiasis			
subjects affected / exposed	7 / 284 (2.46%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Hepatic fibrosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hepatic function abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hepatic steatosis			
subjects affected / exposed	5 / 284 (1.76%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	6	2	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			

subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	4	1	1
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	2	1	1
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Blood bilirubin increased			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Blood calcium increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	10 / 284 (3.52%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences (all)	10	0	2
Blood creatinine increased			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Blood folate decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood glucose abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood glucose increased			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	5	1	1
Blood potassium decreased			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Blood potassium increased			

subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Blood pressure increased			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Blood sodium decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
C-reactive protein increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood uric acid decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Blood urine present			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Body temperature increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Blood urea increased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Carbohydrate antigen 19-9 increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Carcinoembryonic antigen increased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Cardiac murmur			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Carotid bruit			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram abnormal			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Haemoglobin decreased			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Glomerular filtration rate decreased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Haematocrit decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Heart rate decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Heart rate irregular			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Hepatic enzyme increased			
subjects affected / exposed	9 / 284 (3.17%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	9	2	0
International normalised ratio increased			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Intraocular pressure increased			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Neutrophil count increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lipoprotein increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Liver function test abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Liver function test increased			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Mean cell volume increased			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Lipoprotein (a) increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Platelet count decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vitamin D decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Prostatic specific antigen increased			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Pulmonary function test decreased			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Pulse absent			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
QRS axis abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
SARS-CoV-2 test positive			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Sinus rhythm			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Spirometry abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Streptococcus test positive			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Thyroid function test abnormal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Troponin T increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Urine analysis abnormal			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Vitamin B12 decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Platelet count increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Weight decreased			

subjects affected / exposed	1 / 284 (0.35%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	1	2	0
Weight increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
White blood cell count increased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Back injury			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Anaemia postoperative			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Animal bite			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Ankle fracture			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Arthropod bite			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Bone contusion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Burns second degree			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cervical vertebral fracture			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Chest injury			

subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Concussion			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	3 / 90 (3.33%)
occurrences (all)	2	0	3
Contusion			
subjects affected / exposed	15 / 284 (5.28%)	3 / 87 (3.45%)	2 / 90 (2.22%)
occurrences (all)	18	5	3
Forearm fracture			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Eye contusion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Facial bones fracture			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Fall			
subjects affected / exposed	24 / 284 (8.45%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	34	3	1
Fibula fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Foot fracture			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	4	1	0
Epicondylitis			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	5	1	0
Foreign body			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hand fracture			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Head injury			

subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Hip fracture			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Incisional hernia			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Incorrect dose administered			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	3 / 90 (3.33%)
occurrences (all)	2	1	3
Injection related reaction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	3
Injury			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Joint dislocation			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Joint injury			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Ligament rupture			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Ligament sprain			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	6	0	0
Inflammation of wound			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Muscle strain			

subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Muscle rupture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Overdose			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Patella fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Periorbital haematoma			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Post procedural complication			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Post procedural oedema			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Post procedural swelling			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Lip injury			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lower limb fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Lumbar vertebral fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Medication error			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Meniscus injury			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Musculoskeletal injury			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Post-traumatic pain			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Postoperative ileus			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Procedural pain			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	3	1	1
Product dispensing error			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Radius fracture			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Reactive gastropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Thermal burn			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Road traffic accident			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	3	1	2
Skin abrasion			
subjects affected / exposed	6 / 284 (2.11%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	6	0	1
Skin laceration			

subjects affected / exposed	2 / 284 (0.70%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	2	3	0
Sunburn			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Tendon injury			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Tendon rupture			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Rib fracture			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Tibia fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Tooth fracture			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Traumatic haematoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Traumatic liver injury			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Traumatic shock			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Wrist fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences (all)	1	0	2
Ulnar nerve injury			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Upper limb fracture			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vaccination complication			
subjects affected / exposed	6 / 284 (2.11%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Wound			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Wound haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Ulna fracture			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Wrong dose			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Corneal dystrophy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hydrocele			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	17 / 284 (5.99%)	5 / 87 (5.75%)	4 / 90 (4.44%)
occurrences (all)	20	6	4
Aortic valve incompetence			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Aortic valve stenosis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Arrhythmia			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Atrioventricular block first degree			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Atrial flutter			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Atrial thrombosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Atrial fibrillation			
subjects affected / exposed	10 / 284 (3.52%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	14	2	0
Bradycardia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Bundle branch block left			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Bundle branch block right			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Cardiac failure			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cardiac failure congestive			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Coronary artery aneurysm			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Mitral valve incompetence			

subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Coronary artery occlusion			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Coronary artery stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Dilatation atrial			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Extrasystoles			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Coronary artery disease			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	5	1	1
Mitral valve prolapse			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Palpitations			
subjects affected / exposed	7 / 284 (2.46%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	8	1	1
Pericardial effusion			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Right ventricular dilatation			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Supraventricular tachycardia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Tricuspid valve incompetence			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Ventricular extrasystoles			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Ventricular hypokinesia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Ventricular tachycardia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	2	1
Myocardial ischaemia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Nervous system disorders			
Balance disorder			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Ageusia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Altered state of consciousness			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Amnesia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Anosmia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Burning sensation			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Carotid arteriosclerosis			
subjects affected / exposed	0 / 284 (0.00%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Carotid artery stenosis			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Carpal tunnel syndrome			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	4	2	1
Cerebral haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cerebral infarction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Disturbance in attention			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Cervical radiculopathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cluster headache			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cognitive disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Cubital tunnel syndrome			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0

Diabetic neuropathy			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	3	0	1
Cerebrovascular accident			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	24 / 284 (8.45%)	5 / 87 (5.75%)	4 / 90 (4.44%)
occurrences (all)	27	6	5
Dizziness postural			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Dysarthria			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Epilepsy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Head discomfort			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Muscle tension dysphonia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Hypoaesthesia			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	2 / 90 (2.22%)
occurrences (all)	4	2	2
Loss of consciousness			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lumbosacral radiculopathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Memory impairment			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Migraine			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	2	3	1
Migraine with aura			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	21 / 284 (7.39%)	7 / 87 (8.05%)	8 / 90 (8.89%)
occurrences (all)	26	8	11
Nerve compression			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Nervous system disorder			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	2	2	0
Occipital neuralgia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Ophthalmic migraine			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Presyncope			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	5	1	1
Parkinson's disease			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Parkinsonism			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Piriformis syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Polyneuropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Post herpetic neuralgia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	7 / 284 (2.46%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	8	3	1
Restless legs syndrome			
subjects affected / exposed	1 / 284 (0.35%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	1	3	0
Sciatica			
subjects affected / exposed	3 / 284 (1.06%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	3	3	1
Sensory loss			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Somnolence			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Syncope			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	6	2	0
Tremor			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Vascular dementia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Taste disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	6 / 284 (2.11%)	2 / 87 (2.30%)	4 / 90 (4.44%)
occurrences (all)	6	2	4
Eosinophilia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Increased tendency to bruise			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Iron deficiency anaemia			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	4	2	1
Lymphadenopathy			
subjects affected / exposed	1 / 284 (0.35%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	1	2	0
Neutropenia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Thrombocytopenia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
White blood cell disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Microcytic anaemia			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Ear and labyrinth disorders			
Deafness bilateral			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Deafness neurosensory			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Deafness unilateral			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	4	0	1
Ear swelling			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Excessive cerumen production			
subjects affected / exposed	2 / 284 (0.70%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	2	3	1
Tinnitus			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	2	2	1
Vertigo			
subjects affected / exposed	9 / 284 (3.17%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	9	3	1
Vertigo positional			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Vestibular disorder			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Hypoacusis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Cataract			
subjects affected / exposed	15 / 284 (5.28%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	20	3	0
Chalazion			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0

Conjunctival haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Glaucoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	2
Dacryostenosis acquired			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Diplopia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Dry eye			
subjects affected / exposed	4 / 284 (1.41%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	4	3	0
Entropion			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Epiretinal membrane			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Eye swelling			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Corneal erosion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Meibomianitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Metamorphopsia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1

Ocular hypertension			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Photophobia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Meibomian gland dysfunction			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Iritis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lacrimal mucocoele			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lacrimation decreased			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Macular degeneration			
subjects affected / exposed	4 / 284 (1.41%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	4	1	2
Macular hole			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Retinal artery embolism			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Retinal haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Retinal vein occlusion			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Retinopathy hypertensive			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1

Vision blurred			
subjects affected / exposed	1 / 284 (0.35%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	1	2	1
Visual impairment			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Vitreous detachment			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vitreous floaters			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	10 / 284 (3.52%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	10	0	0
Abdominal distension			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Abdominal hernia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Abdominal pain			
subjects affected / exposed	13 / 284 (4.58%)	3 / 87 (3.45%)	4 / 90 (4.44%)
occurrences (all)	15	3	6
Abdominal pain lower			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Abdominal pain upper			
subjects affected / exposed	5 / 284 (1.76%)	2 / 87 (2.30%)	3 / 90 (3.33%)
occurrences (all)	7	3	4
Anal haemorrhage			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			

subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Dysphagia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	7 / 284 (2.46%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	7	2	0
Dry mouth			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Diverticulum intestinal			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	2	2	0
Diverticulum			
subjects affected / exposed	5 / 284 (1.76%)	4 / 87 (4.60%)	1 / 90 (1.11%)
occurrences (all)	6	4	1
Barrett's oesophagus			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Dental caries			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Defaecation urgency			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Constipation			
subjects affected / exposed	15 / 284 (5.28%)	5 / 87 (5.75%)	5 / 90 (5.56%)
occurrences (all)	15	5	5
Colitis ulcerative			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Chronic gastritis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Buccal polyp			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	17 / 284 (5.99%)	9 / 87 (10.34%)	3 / 90 (3.33%)
occurrences (all)	18	9	3
Enteritis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Faeces discoloured			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Food poisoning			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gastric disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gastric ulcer			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Gastritis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Gastritis erosive			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal scarring			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			

subjects affected / exposed	6 / 284 (2.11%)	5 / 87 (5.75%)	2 / 90 (2.22%)
occurrences (all)	6	6	2
Haematochezia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Flatulence			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Hiatus hernia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Haemorrhoids			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	5	1	2
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	6	2	0
Intestinal polyp			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Irritable bowel syndrome			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Large intestine polyp			
subjects affected / exposed	9 / 284 (3.17%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	10	3	1
Levator syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Malpositioned teeth			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Melaena			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Mouth ulceration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	18 / 284 (6.34%)	6 / 87 (6.90%)	3 / 90 (3.33%)
occurrences (all)	19	6	3
Impaired gastric emptying			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Oesophageal obstruction			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Oesophageal spasm			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	9	1	2
Umbilical hernia			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Toothache			
subjects affected / exposed	8 / 284 (2.82%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	8	0	0
Tooth disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Swollen tongue			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Salivary gland enlargement			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Salivary gland disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Rectal polyp			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Rectal haemorrhage			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	8	0	0
Oesophagitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Pancreatic failure			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pancreatic steatosis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Acne			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Actinic elastosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Actinic keratosis			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	6	1	1
Blister			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1

Lichen planus			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Dermatitis			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	2	1	1
Dry skin			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Ecchymosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Eczema			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	2 / 90 (2.22%)
occurrences (all)	4	2	2
Eczema nummular			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	6	0	0
Hand dermatitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hidradenitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hyperhidrosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hyperkeratosis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Ingrowing nail			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0

Keloid scar			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Dermal cyst			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Lichenoid keratosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nail dystrophy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Neurodermatitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	4	1	0
Penile ulceration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Precancerous skin lesion			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	11 / 284 (3.87%)	3 / 87 (3.45%)	2 / 90 (2.22%)
occurrences (all)	16	4	2
Psoriasis			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0

Rash			
subjects affected / exposed	11 / 284 (3.87%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	11	1	2
Rash erythematous			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	2
Rosacea			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Scab			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nail discolouration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Skin depigmentation			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Skin fissures			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Skin induration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	6 / 284 (2.11%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	6	1	0
Skin ulcer			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Stasis dermatitis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Vitiligo			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0

Xanthoma			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Albuminuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Acute kidney injury			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Bladder cyst			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Calculus bladder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Chronic kidney disease			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	1	1	1
Cystitis noninfective			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Dysuria			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Glycosuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Microalbuminuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hydronephrosis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hypertonic bladder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Incontinence			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Leukocyturia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Lower urinary tract symptoms			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Haematuria			
subjects affected / exposed	9 / 284 (3.17%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	12	3	1
Nephrolithiasis			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Nephropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	3	0	1
Polyuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Myoglobinuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Renal artery stenosis			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Renal colic			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Renal cyst			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	4	3	0
Micturition disorder			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Micturition urgency			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Proteinuria			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Renal failure			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Renal impairment			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	3	1	1
Ureteral disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Urinary incontinence			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Urinary retention			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Urinary tract discomfort			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			

Hypothyroidism			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	4	2	1
Goitre			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Hyperthyroidism			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Thyroid cyst			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Thyroid mass			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	40 / 284 (14.08%)	10 / 87 (11.49%)	10 / 90 (11.11%)
occurrences (all)	53	17	11
Arthritis			
subjects affected / exposed	5 / 284 (1.76%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	5	4	1
Arthritis reactive			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Axillary mass			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	28 / 284 (9.86%)	13 / 87 (14.94%)	1 / 90 (1.11%)
occurrences (all)	36	14	1
Coccydynia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Bone pain			

subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Bursitis			
subjects affected / exposed	9 / 284 (3.17%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	10	0	0
Cervical spinal stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Chondropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Bone atrophy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Costochondritis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Dupuytren's contracture			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Enthesopathy			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Exostosis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Exostosis of jaw			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Femoroacetabular impingement			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Fibromyalgia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Finger deformity			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Foot deformity			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Intervertebral disc disorder			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Intervertebral disc protrusion			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Joint stiffness			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Joint swelling			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Limb discomfort			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Loose body in joint			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	15 / 284 (5.28%)	2 / 87 (2.30%)	6 / 90 (6.67%)
occurrences (all)	19	2	6
Muscle tightness			

subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Osteitis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal chest pain			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	6	1	0
Musculoskeletal pain			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Musculoskeletal stiffness			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Myalgia			
subjects affected / exposed	24 / 284 (8.45%)	3 / 87 (3.45%)	7 / 90 (7.78%)
occurrences (all)	28	4	7
Neck pain			
subjects affected / exposed	4 / 284 (1.41%)	2 / 87 (2.30%)	1 / 90 (1.11%)
occurrences (all)	4	2	1
Muscular weakness			
subjects affected / exposed	5 / 284 (1.76%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	6	1	2
Osteoarthritis			
subjects affected / exposed	16 / 284 (5.63%)	6 / 87 (6.90%)	2 / 90 (2.22%)
occurrences (all)	18	6	2
Osteochondrosis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Osteopenia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Osteoporosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Rheumatoid arthritis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Periarthritis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Plantar fasciitis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Polyarthritis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Polymyalgia rheumatica			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Pain in extremity			
subjects affected / exposed	25 / 284 (8.80%)	6 / 87 (6.90%)	1 / 90 (1.11%)
occurrences (all)	29	7	1
Spinal osteoarthritis			
subjects affected / exposed	6 / 284 (2.11%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Spinal pain			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Spinal stenosis			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Spondyloarthropathy			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Spondylolisthesis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Synovial cyst			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Spinal deformity			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Tendon pain			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Tendonitis			
subjects affected / exposed	3 / 284 (1.06%)	4 / 87 (4.60%)	1 / 90 (1.11%)
occurrences (all)	3	4	1
Rotator cuff syndrome			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	3	1	1
Shoulder deformity			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Sjogren's syndrome			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Synovitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Tenosynovitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Trigger finger			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	6	0	0
Infections and infestations			
Acarodermatitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Abscess			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Abscess of eyelid			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Bronchitis			
subjects affected / exposed	15 / 284 (5.28%)	4 / 87 (4.60%)	3 / 90 (3.33%)
occurrences (all)	19	5	3
Balanitis candida			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Candida infection			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Cellulitis			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Clostridium difficile infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	4	1	0
Corneal infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Coronavirus infection			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Cystitis			
subjects affected / exposed	5 / 284 (1.76%)	6 / 87 (6.90%)	2 / 90 (2.22%)
occurrences (all)	6	8	2
Diarrhoea infectious			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Acute sinusitis			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Asymptomatic bacteriuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0

Bacterial infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Bacteriuria			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Diverticulitis			
subjects affected / exposed	5 / 284 (1.76%)	2 / 87 (2.30%)	2 / 90 (2.22%)
occurrences (all)	5	2	2
Ear infection			
subjects affected / exposed	1 / 284 (0.35%)	5 / 87 (5.75%)	1 / 90 (1.11%)
occurrences (all)	1	6	1
Ear lobe infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Erysipelas			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Escherichia bacteraemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
External ear cellulitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Eye infection			
subjects affected / exposed	3 / 284 (1.06%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Folliculitis			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Fungal infection			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	6	0	0

Fungal skin infection			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	3	0	1
Furuncle			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	12 / 284 (4.23%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	12	0	1
Gastroenteritis bacterial			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Gastroenteritis viral			
subjects affected / exposed	8 / 284 (2.82%)	2 / 87 (2.30%)	2 / 90 (2.22%)
occurrences (all)	8	2	2
Genital herpes simplex			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Genital infection fungal			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Gingivitis			
subjects affected / exposed	0 / 284 (0.00%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	0	3	0
Helicobacter infection			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Hepatitis C			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Herpes simplex			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Influenza			
subjects affected / exposed	36 / 284 (12.68%)	10 / 87 (11.49%)	6 / 90 (6.67%)
occurrences (all)	42	12	8

Hordeolum			
subjects affected / exposed	5 / 284 (1.76%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	7	0	0
Impetigo			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Infective exacerbation of bronchiectasis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	12 / 284 (4.23%)	3 / 87 (3.45%)	1 / 90 (1.11%)
occurrences (all)	13	3	1
Kidney infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Orchitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Labyrinthitis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Localised infection			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Lower respiratory tract infection			
subjects affected / exposed	11 / 284 (3.87%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	23	3	1
Mastitis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nail infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	55 / 284 (19.37%)	13 / 87 (14.94%)	6 / 90 (6.67%)
occurrences (all)	73	14	7
Onychomycosis			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Oral fungal infection			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Oral herpes			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Oral infection			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Klebsiella infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	2	2	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Otitis externa			

subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Otitis media			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Paronychia			
subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Perichondritis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	1 / 90 (1.11%)
occurrences (all)	0	1	1
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	2 / 90 (2.22%)
occurrences (all)	4	1	2
Pneumonia viral			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Postoperative wound infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pulpitis dental			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Pyelonephritis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	3 / 284 (1.06%)	3 / 87 (3.45%)	0 / 90 (0.00%)
occurrences (all)	3	3	0
Retinitis			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Urinary tract infection bacterial			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Root canal infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Sebaceous gland infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	10 / 284 (3.52%)	3 / 87 (3.45%)	3 / 90 (3.33%)
occurrences (all)	11	4	3
Skin infection			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	5	0	0
Staphylococcal infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Suspected COVID-19			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Tinea cruris			
subjects affected / exposed	0 / 284 (0.00%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	0	2	0
Tooth abscess			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0
Tooth infection			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences (all)	4	0	2
Upper respiratory tract infection			
subjects affected / exposed	24 / 284 (8.45%)	5 / 87 (5.75%)	1 / 90 (1.11%)
occurrences (all)	31	7	1
Urethritis			

subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	37 / 284 (13.03%)	7 / 87 (8.05%)	6 / 90 (6.67%)
occurrences (all)	75	19	11
Rhinitis			
subjects affected / exposed	3 / 284 (1.06%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	3	0	0
Vaginal infection			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Varicella zoster virus infection			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vestibular neuronitis			
subjects affected / exposed	0 / 284 (0.00%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	0	1	0
Viral diarrhoea			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Vulvovaginal mycotic infection			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Wound infection			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	2	1	0
Vulvovaginal candidiasis			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	2	0	1
Chlamydial infection			

subjects affected / exposed	0 / 284 (0.00%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Dehydration			
subjects affected / exposed	4 / 284 (1.41%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	4	0	0
Diabetes mellitus			
subjects affected / exposed	32 / 284 (11.27%)	6 / 87 (6.90%)	0 / 90 (0.00%)
occurrences (all)	37	7	0
Hyperglycaemia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Dyslipidaemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Fluid retention			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Glucose tolerance impaired			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	2 / 90 (2.22%)
occurrences (all)	2	0	2
Gout			
subjects affected / exposed	12 / 284 (4.23%)	5 / 87 (5.75%)	1 / 90 (1.11%)
occurrences (all)	18	5	1
Haemochromatosis			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Diabetes mellitus inadequate control			
subjects affected / exposed	8 / 284 (2.82%)	6 / 87 (6.90%)	0 / 90 (0.00%)
occurrences (all)	9	6	0

Hyperuricaemia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypertriglyceridaemia			
subjects affected / exposed	2 / 284 (0.70%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	2	0	0
Hypokalaemia			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	3	2	0
Hypoglycaemia			
subjects affected / exposed	2 / 284 (0.70%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	2	2	0
Hypomagnesaemia			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	1 / 284 (0.35%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	1	1	0
Impaired fasting glucose			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	1 / 90 (1.11%)
occurrences (all)	1	0	1
Increased appetite			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	7 / 284 (2.46%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	7	2	0
Vitamin B12 deficiency			
subjects affected / exposed	1 / 284 (0.35%)	0 / 87 (0.00%)	0 / 90 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	3 / 284 (1.06%)	2 / 87 (2.30%)	0 / 90 (0.00%)
occurrences (all)	4	2	0
Iron deficiency			
subjects affected / exposed	2 / 284 (0.70%)	1 / 87 (1.15%)	0 / 90 (0.00%)
occurrences (all)	3	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 April 2017	Dose was changed from 100mg/0.5mL to 300mg/0.5mL, among other changes.
19 February 2018	Name of the active ingredient was changed to inclisiran, among other changes.
15 March 2019	Secondary and exploratory endpoints were modified, among other changes.
15 May 2019	Group 1 will receive inclisiran only and Group 2 will receive an active comparator + inclisiran, among other changes.
07 October 2020	Sponsor company changed from the Medicines company to Novartis in the protocol, among other changes

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported